PL3515910T3 - Pochodne 5-[2-(pirydyn-2-yloamino)-1,3-tiazol-5-ilo]-2,3-dihydro-1h-izoindol-1-onu i ich zastosowanie jako podwójnych inhibitorów 3-kinazy fosfatydyloinozytolu delta i gamma - Google Patents

Pochodne 5-[2-(pirydyn-2-yloamino)-1,3-tiazol-5-ilo]-2,3-dihydro-1h-izoindol-1-onu i ich zastosowanie jako podwójnych inhibitorów 3-kinazy fosfatydyloinozytolu delta i gamma

Info

Publication number: PL3515910T3
Authority: PL; Poland
Prior art keywords: isoindol; phosphatidylinositol; ylamino; thiazol; pyridin
Prior art date: 2016-09-22

Application number

PL17772381.4T

Other languages

English (en)

Inventor

Matthew Perry

Konstantinos Karabelas

Mickael Mogemark

Peter Bold

Christian Tyrchan

Antonios Nikitidis

Jens Petersen

Ulf BÖRJESSON

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-22

Filing date

2017-09-21

Publication date

2021-02-22

2017-09-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2021-02-22 Publication of PL3515910T3 publication Critical patent/PL3515910T3/pl

Links

JTEFIQCSVCKGDP-UHFFFAOYSA-N 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydroisoindol-1-one Chemical class N1=C(C=CC=C1)NC=1SC(=CN=1)C=1C=C2CNC(C2=CC=1)=O JTEFIQCSVCKGDP-UHFFFAOYSA-N 0.000 title 1
108091007960 PI3Ks Proteins 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
230000009977 dual effect Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17772381.4T 2016-09-22 2017-09-21 Pochodne 5-[2-(pirydyn-2-yloamino)-1,3-tiazol-5-ilo]-2,3-dihydro-1h-izoindol-1-onu i ich zastosowanie jako podwójnych inhibitorów 3-kinazy fosfatydyloinozytolu delta i gamma PL3515910T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662398006P	2016-09-22	2016-09-22
PCT/EP2017/073916 WO2018055040A1 (en)	2016-09-22	2017-09-21	5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number	Publication Date
PL3515910T3 true PL3515910T3 (pl)	2021-02-22

Family

ID=59966739

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17772381.4T PL3515910T3 (pl)	2016-09-22	2017-09-21	Pochodne 5-[2-(pirydyn-2-yloamino)-1,3-tiazol-5-ilo]-2,3-dihydro-1h-izoindol-1-onu i ich zastosowanie jako podwójnych inhibitorów 3-kinazy fosfatydyloinozytolu delta i gamma

Country Status (35)

Country	Link
US (2)	US10961236B2 (pl)
EP (1)	EP3515910B1 (pl)
JP (1)	JP6765516B2 (pl)
KR (1)	KR102226098B1 (pl)
CN (1)	CN109715623A (pl)
AR (1)	AR109706A1 (pl)
AU (1)	AU2017331940B2 (pl)
BR (1)	BR112019004719A2 (pl)
CA (1)	CA3036304A1 (pl)
CL (1)	CL2019000707A1 (pl)
CO (1)	CO2019003440A2 (pl)
CR (1)	CR20190200A (pl)
CY (1)	CY1123346T1 (pl)
DK (1)	DK3515910T3 (pl)
DO (1)	DOP2019000073A (pl)
EA (1)	EA036176B1 (pl)
EC (1)	ECSP19027780A (pl)
ES (1)	ES2818583T3 (pl)
HR (1)	HRP20201175T1 (pl)
HU (1)	HUE051634T2 (pl)
IL (1)	IL265298B (pl)
JO (1)	JOP20190052A1 (pl)
LT (1)	LT3515910T (pl)
MA (1)	MA46268B1 (pl)
MX (2)	MX2019003194A (pl)
PE (1)	PE20190909A1 (pl)
PH (1)	PH12019500615A1 (pl)
PL (1)	PL3515910T3 (pl)
PT (1)	PT3515910T (pl)
RS (1)	RS60764B1 (pl)
SI (1)	SI3515910T1 (pl)
SV (1)	SV2019005857A (pl)
TW (1)	TW201813967A (pl)
UA (1)	UA123558C2 (pl)
WO (1)	WO2018055040A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11161838B2 (en)	2018-11-13	2021-11-02	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en)	2018-11-13	2021-08-03	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Substituted heterocyclic derivatives as pi3k inhibitors
WO2022017371A1 (zh) *	2020-07-21	2022-01-27	中国医药研究开发中心有限公司	具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en)	2020-07-29	2022-02-03	Astrazeneca Ab	Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) *	2023-06-08	2024-03-22	英矽智能科技(上海)有限公司	噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE318812T1 (de) *	2000-12-21	2006-03-15	Bristol Myers Squibb Co	Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
GB0305152D0 (en) *	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
US20090233896A1 (en) *	2005-06-09	2009-09-17	Arrington Kenneth L	Inhibitors of checkpoint kinases
TW200911798A (en) *	2007-08-02	2009-03-16	Amgen Inc	PI3 kinase modulators and methods of use
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US9056877B2 (en)	2011-07-19	2015-06-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PE20141371A1 (es)	2011-08-29	2014-10-13	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos
WO2013052699A2 (en)	2011-10-04	2013-04-11	Gilead Calistoga Llc	Novel quinoxaline inhibitors of pi3k
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
TW201446767A (zh)	2013-02-15	2014-12-16	Almirall Sa	作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
CN111153905A (zh)	2013-07-02	2020-05-15	理森制药股份公司	PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
SG11201610745XA (en)	2014-06-27	2017-01-27	Rhizen Pharmaceuticals Sa	Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases

2017
- 2017-06-16 JO JOP/2019/0052A patent/JOP20190052A1/ar unknown
- 2017-09-21 US US16/332,620 patent/US10961236B2/en active Active
- 2017-09-21 EP EP17772381.4A patent/EP3515910B1/en active Active
- 2017-09-21 MA MA46268A patent/MA46268B1/fr unknown
- 2017-09-21 PE PE2019000702A patent/PE20190909A1/es unknown
- 2017-09-21 PL PL17772381.4T patent/PL3515910T3/pl unknown
- 2017-09-21 MX MX2019003194A patent/MX2019003194A/es unknown
- 2017-09-21 BR BR112019004719A patent/BR112019004719A2/pt not_active IP Right Cessation
- 2017-09-21 KR KR1020197010973A patent/KR102226098B1/ko active IP Right Grant
- 2017-09-21 AU AU2017331940A patent/AU2017331940B2/en not_active Ceased
- 2017-09-21 SI SI201730357T patent/SI3515910T1/sl unknown
- 2017-09-21 UA UAA201903648A patent/UA123558C2/uk unknown
- 2017-09-21 RS RS20201077A patent/RS60764B1/sr unknown
- 2017-09-21 CR CR20190200A patent/CR20190200A/es unknown
- 2017-09-21 TW TW106132359A patent/TW201813967A/zh unknown
- 2017-09-21 JP JP2019515477A patent/JP6765516B2/ja not_active Expired - Fee Related
- 2017-09-21 EA EA201990664A patent/EA036176B1/ru not_active IP Right Cessation
- 2017-09-21 HU HUE17772381A patent/HUE051634T2/hu unknown
- 2017-09-21 PT PT177723814T patent/PT3515910T/pt unknown
- 2017-09-21 DK DK17772381.4T patent/DK3515910T3/da active
- 2017-09-21 CN CN201780057289.2A patent/CN109715623A/zh active Pending
- 2017-09-21 LT LTEP17772381.4T patent/LT3515910T/lt unknown
- 2017-09-21 WO PCT/EP2017/073916 patent/WO2018055040A1/en unknown
- 2017-09-21 CA CA3036304A patent/CA3036304A1/en not_active Abandoned
- 2017-09-21 ES ES17772381T patent/ES2818583T3/es active Active
- 2017-09-22 AR ARP170102631A patent/AR109706A1/es unknown
2019
- 2019-03-11 IL IL265298A patent/IL265298B/en active IP Right Grant
- 2019-03-19 CL CL2019000707A patent/CL2019000707A1/es unknown
- 2019-03-20 DO DO2019000073A patent/DOP2019000073A/es unknown
- 2019-03-20 MX MX2021004748A patent/MX2021004748A/es unknown
- 2019-03-21 PH PH12019500615A patent/PH12019500615A1/en unknown
- 2019-03-22 SV SV2019005857A patent/SV2019005857A/es unknown
- 2019-04-08 CO CONC2019/0003440A patent/CO2019003440A2/es unknown
- 2019-04-17 EC ECSENADI201927780A patent/ECSP19027780A/es unknown
2020
- 2020-07-28 HR HRP20201175TT patent/HRP20201175T1/hr unknown
- 2020-09-09 CY CY20201100856T patent/CY1123346T1/el unknown
2021
- 2021-02-11 US US17/173,826 patent/US20210246130A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MA46268B1 (fr)	2020-08-31
EA201990664A1 (ru)	2019-08-30
EP3515910A1 (en)	2019-07-31
IL265298B (en)	2020-09-30
IL265298A (en)	2019-05-30
CL2019000707A1 (es)	2019-05-31
PH12019500615A1 (en)	2019-06-03
CO2019003440A2 (es)	2019-04-12
JOP20190052A1 (ar)	2019-03-21
RS60764B1 (sr)	2020-10-30
SI3515910T1 (sl)	2020-09-30
CA3036304A1 (en)	2018-03-29
MX2021004748A (es)	2021-06-08
ES2818583T3 (es)	2021-04-13
DK3515910T3 (da)	2020-08-31
PT3515910T (pt)	2020-09-16
ECSP19027780A (es)	2019-04-30
KR20190049867A (ko)	2019-05-09
SV2019005857A (es)	2019-05-06
JP6765516B2 (ja)	2020-10-07
EP3515910B1 (en)	2020-07-15
AU2017331940A1 (en)	2019-05-02
MA46268A (fr)	2019-07-31
CY1123346T1 (el)	2022-03-24
TW201813967A (zh)	2018-04-16
US10961236B2 (en)	2021-03-30
CN109715623A (zh)	2019-05-03
WO2018055040A1 (en)	2018-03-29
DOP2019000073A (es)	2019-04-15
BR112019004719A2 (pt)	2019-05-28
KR102226098B1 (ko)	2021-03-09
EA036176B1 (ru)	2020-10-09
AR109706A1 (es)	2019-01-16
CR20190200A (es)	2019-06-07
JP2019529445A (ja)	2019-10-17
AU2017331940B2 (en)	2020-03-12
UA123558C2 (uk)	2021-04-21
HRP20201175T1 (hr)	2020-11-13
HUE051634T2 (hu)	2021-03-01
PE20190909A1 (es)	2019-06-26
MX2019003194A (es)	2019-06-17
US20210246130A1 (en)	2021-08-12
US20200308164A1 (en)	2020-10-01
LT3515910T (lt)	2020-10-12

Publication	Publication Date	Title
HUE051634T2 (hu)	2021-03-01	5-[2-(Piridin-2-il-amino)-1,3-tiazol-5-il]-2,3-dihidro-1H-izoindol-1-on-származékok és alkalmazásuk delta és gamma foszfatidilinozit-3-kináz duális inhibitoraiként
IL276333B (en)	2021-07-29	Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b
SG11202011513RA (en)	2020-12-30	Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
HUE046008T2 (hu)	2020-02-28	I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
EP3191469A4 (en)	2018-03-21	2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
HK1245793B (zh)	2020-01-03	作為adamts抑制劑用於治療骨關節炎的5-[(哌嗪-1-基)-3-氧代-丙基]-咪唑烷-2，4-二酮衍生物
MX2016012687A (es)	2017-04-27	Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
EP3266774A4 (en)	2018-08-08	Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
PL3394083T3 (pl)	2022-01-17	Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazy
EP3162802A4 (en)	2018-01-17	2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
EP3697419A4 (en)	2021-08-18	AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF
SG11201610745XA (en)	2017-01-27	Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
SI3292133T1 (sl)	2019-08-30	Postopek priprave 2-(4-(2-(((2-(4-klorofenil)-1,3-tiazol-4-il)metil)sulfanil)-3,5-dician- 6-(pirolidin-1-il)piridin-4-il)fenoksi)etil-L-alanil-L-alaninat hidroklorida
HK1222655A1 (zh)	2017-07-07	-{ }- -{ -嗎啉基甲基 -吡咯- -基亞甲基}- -氧代- -二氫- -吲哚- -基甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑
PH12017500123B1 (en)	2017-05-29	Crystal of azole benzene derivative
PL3212644T3 (pl)	2021-11-29	Pochodne 2-(1,2,4-triazol-3-ilosulfanylo)-n-1,3,4-tiadiazol-2 -iloacetamidu, które są przydatne w leczeniu cukrzycy
EP3013333A4 (en)	2017-01-11	Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
PH12017500124B1 (en)	2017-05-29	Azole benzene derivative and crystalline form thereof